Switchable Retargeting of Lentiviral Vectors Through a VSV-G-Binding Adapter Molecule.

Vladislav A Zhuchkov, Marat P Valikhov, Yulia E Kravchenko, Elena I Frolova, Stepan P Chumakov

Abstract read

In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Vladislav A ZhuchkovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.ORCID 0009-0008-7536-1325

Marat P ValikhovEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.ORCID 0000-0001-8988-3417

Yulia E KravchenkoShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.

Elena I FrolovaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.ORCID 0000-0003-3551-6528

Stepan P ChumakovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.ORCID 0000-0003-2866-5277

Funding

Russian Science Foundation 23-14-00390

6 · The paper itself

Abstract

Selective gene delivery to defined cell populations remains one of the key challenges in lentiviral vector-based gene therapy. The vesicular stomatitis virus glycoprotein (VSV-G) confers high infectivity but lacks cell-type specificity because of the ubiquitous expression of its receptor, LDLR. To enable modular, receptor-specific targeting while retaining the production efficiency of VSV-G-pseudotyped vectors, we designed a bispecific adapter, 929-B6, comprising a VSV-G-binding nanobody and an ERBB2-binding DARPin 9.29. Anti-VSV-G nanobodies were isolated from an alpaca immune library and screened in cell-based pseudoreceptor assays to identify the optimal binder (VSVG-B6). The resulting adapter was evaluated with receptor-ablated (VSV-G

Indexed as

Genetic VectorsLentivirusMembrane GlycoproteinsViral Envelope ProteinsAnimalsCell LineCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleGenetic TherapyHEK293 CellsHumansMiceSingle-Domain AntibodiesTransduction, GeneticERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesG protein, vesicular stomatitis virusMembrane GlycoproteinsSingle-Domain AntibodiesViral Envelope ProteinsERBB2lentivectornanobodyretargetingVHHVSV-G

Identifiers

PMID41472234

DOI10.3390/v17121563

PMCPMC12737384

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.